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ABSTRACT
Adverse drug events resulting from drug-drug interactions may lead to emergency department visits, hospitalizations, prolonged
length of stays, increased medical care costs, and death. Despite the efforts of research, clinical studies, and active reporting to
identify and explain these drug interaction pathways, clinicians are often unaware of such drug-drug interactions. Therefore, it is
imperative for pharmacists to identify these potential drug-drug interactions and notify the clinicians as well as the patients so
that appropriate safety measures and monitoring methods are implemented. Specifically, immunocompromised patients often
receive multiple drug regimens which are associated with toxicities and are highly susceptible to drug-drug interactions. Because
of the increased use of azole antifungals in the prophylaxis or treatment of invasive fungal infections among these patients, a
close monitoring of drug-drug interactions is warranted. Posaconazole (PCZ), an extended spectrum azole antifungal, has been
indicated for use in the prophylaxis of invasive fungal infections in immunocompromised patients. The intent of this article is to
increase the awareness of the potential drug-drug interactions with PCZ by reviewing the available drug interaction studies of
PCZ and other therapeutic agents, specifically Mylanta, cimetidine, phenytoin, midazolam, cyclosporine, tacrolimus, rifabutin,
and glipizide. Excluding Mylanta and glipizide, significant interactions had been observed when PCZ was co-administered with
these agents. Therefore, avoidance of PCZ with these and other agents which share the same metabolic pathways is
recommended. Otherwise, frequent monitoring of drug levels and for adverse drug events as well as dose adjustments may be
warranted.
INTRODUCTION
Adverse drug events have been an inherent component of medication use. It was not until after the “To Err Is Human: Building a
Safer Health System” report that they became the focus of patient care in all health care environments.1 One possible
contributing factor is the concomitant use of medications that have the potential for clinically significant interactions.2-5 These
adverse drug events resulting from drug-drug interactions may lead to emergency department visits, hospitalizations, prolonged
length of stays, and increased medical care costs as well as death in both inpatient and outpatient settings.3-9 The root cause of
this problem is probably multifactorial. Despite the efforts of research, clinical studies and active reporting to identify and explain
these drug interaction pathways, clinicians are often unaware of such drug-drug interactions.10-14 In order to improve patient
safety and quality of care in the health system, the Joint Commission has established a number of standards and safety goals for
health care practice to improve the safety of using medications and effectiveness of communication among caregivers.15
Regardless of which health care practice environment, it is imperative for pharmacists to identify these potential drug-drug
interactions and notify the clinicians as well as the patients so that appropriate safety measures and monitoring methods are
implemented.
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Immunocompromised patients (i.e., cancer, HIV/AIDS, and solid organ transplantation) often receive multiple and prolonged drug
therapies not only for the treatment of their underlying diseases but also for the treatment and prophylaxis of complications from
their immunocompromised states. These complex drug regimens are associated with toxicities and are highly susceptible to
drug-drug interactions that further complicate their drug regimens. Because of the increased use of azole antifungal agents in the
prophylaxis or treatment of invasive fungal infections among immunocompromised patients, a close monitoring of drug-drug
interactions is warranted.16-19
Posaconazole (PCZ) is an extended spectrum azole antifungal agent with a chemical structure similar to itraconazole. It has
received FDA approval for use in the prophylaxis of invasive fungal infections in particular aspergillosis and candidiasis in high
risk immunocompromised patients who are 13 years or older.20 By disrupting fungal cell wall synthesis, PCZ has fungicidal
activity against Cryptococcus neoformans, Aspergillus (fumigatus, flavus, and terreus), Blastomyces dermatitidis, Trichosporon
and specific Candida species (krusei, parapsilosis, lusitaniae and inconspicua).20, 21 It also has shown fungistatic activity against
most other Candida species, Scedosporium, Coccidiodes, Zygomycetes and specific Fusarium strains (oxysporum and
monilforme).20, 21
PCZ is orally bioavailable and its gastrointestinal absorption is enhanced when co-administered with food or a nutritional
supplement regardless of gastric pH.22-26 In phase I clinical trials, the mean maximum plasma concentration (Cmax) values
(ng/mL) were 555 and 2607 after a single oral 400 mg dose and a multiple oral dose regimen (400 mg twice daily for 8 days) of
PCZ suspension, respectively.27, 28 PCZ has a large apparent volume of distribution (V/F), suggesting extensive tissue
penetration and is highly protein bound (> 98.5%).27, 29 The mean systemic exposure value of PCZ suspension for the single
dose phase was 18425 ng · h/mL whereas the multiple dosing phase was 26740 ng · h/mL.27, 28 The major elimination route of
PCZ is fecal (77%) with a mean apparent systemic clearance (CL/F) of 421 mL/min and a half-life (t½) of 24 hours (h) in a single
400 mg dose study.27 The t½ is longer (~35 h) in multiple dosing studies.28 PCZ is hepatically metabolized into multiple inactive
glucuronides by phase II UDP-glucuronosyltransferase.27 Having a pregnancy category C status, PCZ may be harmful to the
fetus during pregnancy and its safety is uncertain in lactation.20 Therefore, avoidance of PCZ during pregnancy and lactation is
recommended. Otherwise, PCZ is considered safe and well tolerated. The most commonly reported side effects (>10%) in small,
single and/or multiple dosing phase I studies of PCZ, included headache, fatigue, nausea, and dry mouth.22-29 PCZ is available in
the United States as an oral suspension (40 mg/mL). Its dosing regimen ranges from 200 mg daily to three times daily depending
on the disease state.20, 30-33 No dosing adjustment of PCZ is needed in renal failure or dialysis patients.29 The clinical data of PCZ
use in hepatic impairment, bariatric, and pediatric populations are still limited. Routine monitoring of electrolytes and liver function
tests is recommended during PCZ therapy.20
The purpose of this article is to increase the awareness of the potential drug-drug interactions with PCZ when used in
prophylaxis or treatment of invasive fungal infections among immunocompromised patients. Our goals are to promote the safe
use of medications by improving communication among health care providers and to prevent adverse drug events. This article
describes the available clinical drug-drug interaction studies with PCZ and other therapeutic agents specifically Mylanta,
cimetidine, phenytoin, midazolam, cyclosporine, tacrolimus, rifabutin and glipizide.26, 34-37, 39, 40 A brief summary of these studies is
displayed in Table 1.
DRUG REVIEW
Mylanta (antacid)
The over-the-counter Mylanta is known for its use in heartburn and/or dyspepsia. Courtney et al. conducted a randomized, open
label, four way crossover pharmacokinetic study in healthy volunteers (n=12) to evaluate the effect of altering gastric pH on the
relative systemic absorption of PCZ.26 Maximum strength Mylanta, containing aluminum hydroxide and magnesium hydroxide,
was used. The Mylanta dose was 20 mL, which provided a total of 102 mEq of acid neutralizing capacity to increase the gastric
pH above 3.5. After a 10-hour overnight fast, all subjects were randomized to receive a single 200 mg PCZ tablet and 200 mL of
regular water under four different conditions (either alone, immediately after a standardized high fat meal, Mylanta alone, or
Mylanta and a standardized high fat meal).26 A 7-day washout period was used between each study phase. A series of blood
samples were collected according to the study protocol, and plasma PCZ concentrations were measured by standardized high
performance liquid chromatographic (HPLC) methods. The analyses of the data were discussed in detail in the original research
article.26
The baseline characteristics of these subjects were non-obese males with a mean age of 34 years. The races were both blacks
and whites in a 2 to 1 ratio.26 The pharmacokinetic results of this study demonstrated that Mylanta did not significantly alter the
relative systemic absorption of PCZ under all treatment conditions. In the presence of food and Mylanta, the pharmacokinetic
parameters [i.e., Cmax, time to reach Cmax (Tmax), area under the concentration time curve (AUC), t½, CL/F and V/F] were similar
________________________________________________________________________________________________________________________________
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to those in the presence of food only.26 The relative oral bioavailability value of PCZ was estimated to be 88% [90% confidence
interval (Cl): 71%-110%]. Similar effects were observed in the fasting state with or without Mylanta and the corresponding
relative bioavailability of PCZ was 115% [90% CI: 92-143].26 In each group there was intersubject variability of PCZ’s systemic
absorption that ranged from 29% to 45%. This phenomenon concurred with previous studies and remains to be elucidated.22-25,2729 The relative bioavailability of PCZ values were significantly enhanced in the presence of food with or without acid (308%,
p=0.001 and 400%, p=0.001, respectively).26 The rates of absorption remained relatively constant among all study phases. Only
one subject experienced a mild headache. The V/F and CL/F values of PCZ were three fold higher in the fasting state than in the
nonfasting state. The authors explained that these observations were a result of decreased PCZ absorption under fasting
conditions because the elimination rate constants did not change among all four treatment phases.
______________________________________________________________________________________________________
Table 1. Drug Interactions Studies of Posaconazole (PCZ) and Selected Agentsa
PCZ Tab

PCZ Susp

Dose

Dose

Duration of Therapy

Effects on PCZ

Effects on Agent

Cimetidine 400 mg q12h

200 mg qd

ND

10 days

Cmax ¯ 40%
AUC ¯ 40%

ND

Cyclosporine bidb

200 mg qd

ND

10 days

NS

C0 -

Glipizide 10 mgc

ND

400 mg BID

10 days

NS

NS

200 mg qd

ND

10 days

NS

AUC - 83%

Mylanta 20 mL S.D.

200 mg S.D.

ND

One time

NS

ND

Phenytoin 200 mg qd

200 mg qd

ND

10 days

Cmax ¯ 41%
AUC ¯ 50%
CL/F - 90%

Cmax - 16%
AUC - 16%

Rifabutin 300 mg qd

200 mg qd

ND

10 days

Cmax ¯ 43%
AUC ¯ 49%
CL/F - 100%
t½ ¯ 42%

Cmax - 31%
AUC - 72%
CL/F - 42%

ND

400 mg BID

7 days

NS

Cmax - 121%
AUC - 358%
t½CL/F ¯

Drug/Dose

Midazolam 0.05 mg/kg S.D.

Tacrolimus 0.05 mg/kgd

aAll

interactions refer to alterations of PCZ pharmacokinetics unless otherwise stated.
is individualized based on target trough concentrations
cSpecific agent was administered on days 1 and 11
dSpecific agent was administered on days 1 and 14
Tab = Tablet; Susp = Suspension; S.D. = Single dose
Cmax = Maximum plasma concentrations; AUC = area under the plasma concentration versus time curve;
CL/F = Apparent systemic clearance; C0 = whole blood trough concentration; t½ = half-life
kg = kilograms; mg = milligrams; mL = milliliters; q12h = every 12 hours; qd = daily; bid = Twice daily
ND = No data available; NS = No significant interaction
Adapted from references 26, 34-37, 39, and 40; see text for specific discussions and citations
__________________________________________________________________________________________________________________
bDosing

The authors concluded that PCZ oral absorption was independent of gastric pH and was enhanced in the presence of food.26
However, the major concern with this study was the single dose of Mylanta may not be sufficient to sustain a gastric pH above
3.5 for longer than 1 hour since the mean Tmax of PCZ was greater than 7 hours.26 The authors did not postulate an explanation
of their observations in terms of gastric pH on PCZ absorption. Additionally, the effects on PCZ bioavailability from the presence
of a more potent acid suppressant, either a histamine-2 receptor antagonist (H2RA) or a proton pump inhibitor, or from
gastrointestinal disorders (i.e., achlorhydria and spontaneous or drug induced hyperchlorhydria) remain to be determined. At the
present time, concomitant use of an antacid and PCZ appears to be safe and does not affect the systemic exposure of PCZ.
________________________________________________________________________________________________________________________________
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Cimetidine (histamine-2 receptor antagonist)
Cimetidine, one of the oldest H2RA, is known for its use in heartburn, dyspepsia, and/or upper gastrointestinal bleeding by
raising the gastric pH. Cimetidine is also accepted as a CYP3A4 inhibitor. Courtney et al. conducted a randomized, open label,
two-way crossover, multiple dose drug interaction study in which healthy subjects (n=12) were randomly assigned to 10 days of
either PCZ 200 mg tablet PO daily (phase 1) or same dose of PCZ and cimetidine 400 mg PO every 12 hours (phase 2).34 The
two phases were separated by a 7-day washout period. A series of blood samples were collected according to the study
protocol. Blood samples measuring plasma concentrations of PCZ and cimetidine were performed by the standardized HPLC
techniques. The mean Cmax and AUC values of PCZ both decreased by 40% in phase 2 as compared to phase 1.34 The relative
systemic exposure of PCZ in the presence of cimetidine was estimated to be 61% (90% CI: 54%-69%).34 The mean Tmax and t½
values were 7 h and 35 h in both treatment phases. No adverse effect was reported.
The author concluded that a multiple daily PCZ regimen was safe and well tolerated. PCZ absorption is independent of gastric
pH as previously demonstrated with Mylanta. However, the co-administration of PCZ with cimetidine should be avoided because
of the decrease in the relative bioavailability of PCZ at a gastric pH of 3 or greater.20 This discrepancy between the effect of
gastric pH on PCZ’s systemic exposure suggests the presence of other mechanisms, i.e., competition between PCZ and
cimetidine for the same transport protein. The involvement of the CYP450 system and/or other mechanisms on PCZ’s systemic
exposure requires further investigation. If a H2RA is needed, an alternative such as famotidine with minimal or no cytochrome
P450 (CYP450) enzyme system involvement may be used.
Phenytoin (antiepileptic)
Phenytoin is a first generation antiepileptic agent which has a narrow therapeutic index and is metabolized primarily through the
hepatic CYP450 3A4 (CYP3A4) isoenzyme system. The work of Courtney et al. involved a randomized, open label, parallel,
multiple dose study in which healthy subjects (n=36) were randomly assigned to three 10 day treatment arms: PCZ 200 mg tablet
PO daily (group 1), phenytoin 200 mg PO daily (group 2), and the same doses of PCZ and phenytoin (group 3).35 A series of
blood samples were collected according to the study protocol. Blood samples measuring plasma concentrations of PCZ and
phenytoin were performed using validated HPLC methods.
At steady state, the mean relative systemic bioavailability of PCZ was decreased by 50% after the co-administration of oral PCZ
(200 mg tablet daily) and oral phenytoin (200 mg daily) despite no significant change in mean Cmax values between days 1 and
10.35 This phenomenon was explained by the increased CL/F of PCZ by 90% in the presence of phenytoin, an UDPglucuronosyltransferase inducer.35 Conversely, the relative systemic exposure of phenytoin was increased by 16% when coadministered with PCZ.35 The authors suggested that when patients are receiving PCZ, avoidance of phenytoin is warranted.
The magnitudes of the changes in bioavailability of PCZ and phenytoin are still uncertain, because clinically, the dosing with
these agents is different and the toxicity may appear sooner than 10 days. The baseline demographics of these subjects and
adverse effects were not reported. Finally, careful monitoring of phenytoin levels is warranted when both drugs are used
together.
Midazolam (sedative)
Because of its extremely short t½, midazolam continuous infusion is used primarily in the intensive care unit or surgical
procedures as a sedative. The effects of PCZ on the activity of several drug metabolizing CYP450 enzymes were investigated.36
This study used non-obese adult subjects (n=13, age range 18 to 45) who were randomly assigned to receive oral PCZ (200 mg
tablet daily) or no drug for 10 days.36 After a 14 day washout period, subjects crossed over to the alternate study group. A
standardized CYP450 cocktail with corresponding surrogate substrates consisted of caffeine (CYP1A2), tolbutamide
(CYP2C8/9), dextromethorphan (CYP2D6 and total CYP3A4) and chlorzoxazone (CYP2E1). This cocktail was given to both
study groups 2 hours after the administration of PCZ under fasting conditions on day 9. In addition, midazolam (0.05 mg/kg in
100 mL of 0.9% saline), a benzodiazepine which undergoes hepatic CYP3A4 metabolism, was given in place of the CYP450
cocktail on day 10 as a 30 min infusion.36 A series of blood and urine samples were performed according to the study protocol.
Plasma and urine concentrations of PCZ, other CYP450 markers and their metabolites were analyzed by standardized laboratory
techniques.
Steady state PCZ concentrations were reached after 8 days with mean (%Coefficient of variation [CV]) Cmax (ng/mL), Tmax (h),
AUC (ng · h/mL), and CL/F (mL/min) values of PCZ were 1073 (31), 6.9 (21), 19,465 (32), and 188 (34), respectively.36 Based
on the aforementioned information under fasting conditions, the systemic exposure of oral PCZ 200 mg tablets showed an
accumulation index of 1.9. Plasma- or urine ratios of CYP450 markers and their metabolites were examined to assess the effects
of PCZ on the CYP450 isoenzymes. Plasma ratios of 1,7-dimethylxanthine to caffeine and 6-hydroxychlorzoxazone to
chlorzoxazone were examined in order to assess CYP1A2 and CYP2E1 activities, respectively. Urinary ratios of combined 4________________________________________________________________________________________________________________________________
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hydroxytolbutamide + carboxytolbutamide and tolbutamide, dextromethorphan and dextrorphan and dextromethorphan and 3methoxymorphinan were measured in order to assess the effects of CYP2C8/9, CYP2D6 and total (intestinal and hepatic)
CYP3A4, respectively. Furthermore, hepatic CYP3A4 activity was measured when midazolam was given with PCZ. Overall, PCZ
did not affect the CYP450 isoenzymes 1A2, 2C8/9, 2D6, 2E1 and total CYP3A4 with the exception of hepatic CYP3A4. The
inhibitory effect of PCZ on hepatic CYP3A4 is demonstrated by a significant increased mean AUC (%CV) (ng · h/mL) of
midazolam in the presence of PCZ as compared to in the absence of PCZ [93.4 (29) vs. 51.4 (29), respectively, p<0.01].36 This
results in a relative 1.83 (90% CI: 1.57 to 2.14) fold increase in midazolam exposure.37 The authors concluded that unlike other
azole antifungal agents (i.e., itraconazole and ketoconazole), PCZ has limited potential drug interactions because of its sole
inhibition of hepatic CYP3A4.
Interestingly, this study demonstrated that PCZ is a potent CYP3A4 inhibitor by reducing the CL/F of midazolam. In clinical
practice, the pharmacological effect of midazolam can be assessed based on a sedation protocol. Dosing of midazolam can be
done by adjusting the rate of infusion. The reason why PCZ had no effect on the total CYP3A4 activity remained to be elucidated
because intestinal interactions among the CYP450 markers could not be excluded. Complete voiding of the urinary bladder to
measure each CYP450 marker and its metabolites was questionable. Overall, the ideal approach is to avoid co-administration of
PCZ with other CYP3A4 substrates which include an extensive list of drugs, including but not limited to calcium channel blockers,
calcineurin inhibitors, ergot alkaloids, HIV-1 protease inhibitors, HMG-CoA reductase inhibitors and vinca alkaloids.2
Cyclosporine and tacrolimus (calcineurin inhibitors)
Cyclosporine (CSA) and tacrolimus (FK506) belong to a class of immunosuppressants called calcineurin inhibitors which play a
major role as maintenance therapy in the prevention of acute allogeneic graft rejection in solid organ transplantation. Both CSA
and FK506 are CYP3A4 and P-glycoprotein (P-gp) substrates.16 Previous studies reported that PCZ undergoes extensive
hepatic metabolism yielding glucuronide metabolites.27 PCZ is also a hepatic CYP3A4 enzyme inhibitor as discussed
previously.36 Sansone-Parsons et al. examined the effects of oral PCZ on the systemic exposures of CSA and FK506 in two
separate, open label, and single center, drug interaction studies.37 The CSA-PCZ study was conducted in heart transplant
recipients (n=4) who had normal cardiac function and resided in United States, whereas the FK506-PCZ study was performed in
healthy volunteers (n=36) who lived in England. Subjects were excluded from both studies if they were tested positive for
hepatitis B surface antigen, hepatitis C antibody and human immunodeficiency virus (HIV) antibodies. A series of blood samples
were collected according to the study protocol. All study drug concentrations were analyzed by liquid chromatography and mass
spectrometry techniques.
In the CSA-PCZ study, patients were excluded if they were smokers, strict vegetarians, or blood donors within the past 3 months.
Other exclusions included a history of mental illness, receiving treatment for mood disorders, and medications that can interact
with CSA as specified in the article.37 Heart transplant recipients receiving a stable CSA regimen for 6 weeks or longer were
administered oral PCZ 200 mg tablet daily for 10 days.37 PCZ was administered in the evening on day 1 and after a high fat
content breakfast from day 2 to 10. The investigators adjusted the CSA dose for each subject depending on corresponding
trough concentration (C0).
The heart transplant recipients in the CSA-PCZ study were all Caucasian males with a mean age of 54 years. The authors stated
that steady state plasma PCZ concentrations increased CSA C0 levels which led to CSA dosage reductions (ranging from 14% to
29%) in three out of the four patients.37 Adverse effects that were considered drug related in this study included diarrhea,
nonherpetic cold sores, dysuria, flank pain, hematuria, urinary tract infection, pain, rash, and gastritis.37 Although there are a few
critical issues on the design and results of this study, co-administration of PCZ and CSA requires frequent monitoring of CSA C0
concentrations to ensure transplant therapeutic ranges are maintained.38 The authors suggested that three fourths of the original
dosage reduction of CSA should be done when initiating PCZ therapy. However, caution should be employed with this approach
because the recommendation was based on data from three subjects, CSA C0 concentrations and their changes were not
reported, acute graft rejection rate was not evaluated, and the therapeutic dose of PCZ is higher than the one used in this study.
In the other study, Sansone-Parsons et al. examined the effects of PCZ on FK506. Healthy adult subjects received a single PO
dose of FK506, 0.05 mg/kg on days 1 and 14 after a 10 hour fast. PCZ was administered as a 400 mg PO suspension twice daily
from days 7 to 14 after a high fat breakfast.37 This allowed for a 5-day washout period of FK506.
The baseline characteristics of these subjects included non-obese, 50% male, 92% Caucasians with a mean age of 26 years.
The results of this study demonstrated that PCZ significantly increased the systemic exposure of FK506. The means (%CV) Cmax
(ng/mL) and AUC (ng · h/mL) values of FK506 in the absence and presence of PCZ were 24.2 (31) vs. 51.7 (18) and 207 (52)
vs. 875 (27), respectively.37 The mean (%CV) t½ , and CL/F values of FK506 in the presence of PCZ were 35.9 (10) h and 4.31
________________________________________________________________________________________________________________________________
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(30) liter/h, respectively.37 The corresponding values of FK506 when given alone were 29 (15) h and 21.4 (56) liter/h,
respectively.37 The median (range) Tmax (hours) values were the same in both study phases [1.5 (1-3)]. The two most common
adverse effects reported during co-administration of FK506 and PCZ were mild to moderate paresthesia (56%) and headache
(39%).37 Overall, the authors suggested that one third of the original dosage reduction of FK506 should be done when initiating
PCZ therapy. Again, caution should be taken with this suggestion based upon similar reasons as mentioned earlier in the CSA
study.
In the above studies, the pharmacokinetic properties of PCZ were similar to those previously reported when co-administered with
CSA or FK506. However, a wide range of intersubject variability of plasma PCZ concentrations (74%-141% and 30% in CSAPCZ and FK506-PCZ study, respectively) was reported.37 This variation in pharmacokinetic profile of PCZ remains to be
elucidated. Conversely, the changes in the C0 of CSA and AUC of FK506 were postulated by the inhibition of CYP3A4
metabolism and of P-gp transport mediated by PCZ. Until further information is generated on the interaction pathways,
avoidance of these combinations is necessary. Otherwise, close monitoring of CSA or FK506 concentrations is warranted when
these drugs are co-administered with PCZ.
Rifabutin (rifamycin derivative)
Rifabutin, a rifamycin derivative, has a role in the prevention and treatment of mycobacterium related tuberculosis or
opportunistic infection in immunocompromised individuals. Krishna et al. conducted a nonrandomized, open label, parallel,
multiple dose pharmacokinetic study in healthy volunteers (n=24) to evaluate the interaction between PCZ and rifabutin at steady
state.39 Subjects were randomly assigned to receive either PCZ alone for 10 days (group 1) or rifabutin co-administered with
PCZ for 10 days (group 2). Subjects received daily doses of PCZ (tablet, 200 mg) and rifabutin (capsule, 300 mg). In group 2,
steady state levels of rifabutin were established 7 days (days -7 to 1) prior to the administration of PCZ (from days 1-10). Blood
samples were collected according to the study protocol. Plasma PCZ and rifabutin concentrations were measured by
standardized HPLC techniques.
Study subjects included Caucasians males with a mean age (range) of 27 (20 to 40) years and with a mean weight of 73 kg.39
Four subjects in group 2 did not complete the study because of adverse reactions (i.e., leukopenia in 3 subjects and dizziness,
headache and fever in the other). The mean (%CV) Cmax (ng/mL), AUC (ng · h/mL) and median (range) Tmax (h) of PCZ were 766
(37), 12629 (43) and 5 (5-15), respectively.39 The pharmacokinetic parameters of PCZ were significantly altered by rifabutin
(group 2). The mean (%CV) of Cmax (ng/mL), AUC (ng · h/mL), and median (range) Tmax (h) were 428 (29), 6389 (38) and 7 (310), respectively.39 Co-administration of rifabutin resulted in a 43% and 49% reduction in Cmax and AUC of PCZ, respectively.
This reduction in PCZ systemic exposure was associated with a 2-fold increase in PCZ clearance (CL/F, 307 vs. 594 mL/min)
and a 42% decrease in PCZ t½ (27.4 vs. 15.9 hours).39 In group 2, the two consecutive mean rifabutin C0s (ng/mL) on day -1 and
day 1 of PCZ co-administration were comparable (64.1 vs. 72.1).39
Interestingly, the pharmacokinetics of rifabutin were altered by PCZ. The mean (%CV) of Cmax (ng/mL) and AUC (ng · h/mL)
values of rifabutin were 438 (23) and 3975 (20) respectively, on day 1 and 569 (20) and 6833 (21) respectively, on day 10.39
According to these data, co-administration of PCZ with rifabutin resulted in a 31% and 72% increase in Cmax and AUC values,
respectively. This increase in rifabutin exposure was associated with a 42% decrease in total rifabutin clearance as compared to
rifabutin administered alone (CL/F, 1300 vs. 758 mL/min).39
In comparison, the frequency of adverse events was mild in nature and was observed more often in group 2 than in group 1. In
group 1, these possible drug related adverse events included back pain (25%), cough (17%) and dry skin (17%) whereas
headache (75%), back pain (67%), leukopenia (42%), eye abnormality (42%), and abdominal pain (42%) were observed in group
2.39 Leukopenia was the only abnormal laboratory finding in both study groups. The authors concluded that co-administration of
PCZ and rifabutin should be avoided and should be used only if the benefits outweigh the risks. Intense monitoring for adverse
events is needed if PCZ and rifabutin are used together. These observations may be explained by the enhanced systemic
clearance of PCZ by rifabutin (via induction of UDP-glucuronosyltransferase) and the decline of systemic clearance of rifabutin
by PCZ (via CYP3A4 inhibition).
Glipizide
Glipizide is an oral hypoglycemic agent which undergoes renal excretion. Courtney et al. conducted an open label, crossover
study to evaluate the effect of glipizide on the relative bioavailability of PCZ in healthy volunteers (n=12).40 The glipizide dose
was 10 mg on days 1 and 11, whereas the PCZ dose was 400 mg twice daily from day 2 to 11. The authors found that glipizide
had no effect on the relative bioavailability of PCZ and vice versa. Therefore, concomitant use of PCZ and glipizide is considered
safe despite a non-clinical significant decrease in blood glucose.
________________________________________________________________________________________________________________________________
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CONCLUSION
Increased awareness of potential drug-drug interactions of medication use is one key factor in preventing adverse drug events
and promoting safe medications use. Regardless of which health care practice environment, it is imperative for pharmacists to
identify potential drug-drug interactions and notify the health care practitioners and patients so that appropriate safety measures
and monitoring methods are implemented. Because of the unique spectrum of activity and pharmacological profile, PCZ will be
used more frequently in the prophylaxis for invasive fungal infections in patients who are immunocompromised. PCZ is a
CYP3A4 inhibitor and has been shown to interact with a number of CYP3A4 substrates or inhibitors including cimetidine,
phenytoin, midazolam, cyclosporine, tacrolimus, and rifabutin. Therefore, avoidance of PCZ with these and other agents that
share the same metabolic pathways is recommended. Other agents include calcium channel blockers, calcineurin inhibitors,
ergot alkaloids, HIV-1 protease inhibitors, HMG-CoA reductase inhibitors, proton pump inhibitors, and vinca alkaloids. Otherwise,
frequent monitoring of drug levels and for adverse drug events as well as dose adjustments may be warranted. Information
regarding the exact drug-drug interaction pathways between PCZ and the aforementioned agents is still limited and require
further investigation.
______________________________________________________________________________________________________
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